Zeta MTAP Antibody. Zeta’s recombinant rabbit antibody recognizes MTAP (Methylthioadenosine Phosphorylase), an enzyme involved in the metabolism of methionine and purine salvage pathways, is significant in cancer research because its deficiency is associated with some types of cancer. The gene encoding MTAP is located on chromosome 9p21telomeric to p16INK4A/CDKN2A tumor suppressor gene. Inactivation of the p16INK4A/CDKN2A gene occurs by three mechanisms: hypermethylation of the gene promoter, intragenic mutation coupled with loss of the second allele, and homozygous deletion. Since the MTAP gene is often co-deleted with p16INK4A/CDKN2A, concurrent immunolabeling for both proteins can identify cases with homozygous p16INK4A/CDKN2A gene deletion. Loss of MTAP labeling occurred exclusively in conjunction with loss of p16 labeling is seen in patients with mesothelioma, urothelial carcinoma, Barrett’s esophagus with dysplasia, esophageal carcinoma, malignant melanoma, and gliomas.
MTAP loss by immunohistochemistry was 78% sensitive and 96% specific for CDKN2A homozygous deletion. MTAP immunohistochemistry is a reliable surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant mesothelioma (MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma | Modern Pathology).
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.